Intensified Methotrexate, Nelarabine (Compound 506U78; IND# 52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia
The overall goal of this study is to see if we can increase the cure rate for T-cell ALL with acceptable side effects of therapy.
Patients must be between 1-30 years of age Newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) Patients shall have had no prior cytotoxic chemotherapy with the exception of steroids and/or IT cytarabine.
Subjects (people participating in the study) will receive a standard treatment plan during Part I of this study. Standard treatment includes chemotherapy. Standard treatment for ALL has several phases. In the first phase, called Induction, we try to remove all visible signs of leukemia and allow normal blood cells to be restored. This is called remission. You have currently completed the Induction phase of therapy. In the middle phases, called Consolidation, Interim Maintenance and Delayed Intensification, we try to deliver a ?knock-out punch? to any remaining leukemia cells. In the final phase, called Maintenance, we try to keep the leukemia from coming back (disease remission is when the leukemia cells seem to have disappeared). All phases of treatment are very important. The total length of treatment is 2 ½ to 3 years, but does vary.
09/21/2014 04:03 AM